ADRA1A and COVID-19: More recently, we showed elevated levels of AAB directed against several vaso- and immunoregulatory G-protein coupled receptors (GPCRs), including RAS-related proteins, in moderate and severe acute COVID-19 patients being associated with clinical severity of COVID-19 (19).